

Scott Alfred Fretzin, MD

Dawes Fretzin Clinical Research Group, LLC
8103 Clearvista Parkway, Suite 260
Indianapolis, Indiana 46256
Phone (317) 621-7731 Ex 115
Fax (317) 621-7784
Email: DFCRGFretzin@ecommunity.com

Dawes Fretzin Dermatology Group, LLC
8103 Clearvista Parkway, Suite 220
Indianapolis, Indiana 46256
Phone (317) 621-7790 Ex 115
Fax (317) 621-7791

Education

Indiana University School of Medicine (Indianapolis, IN)
Dermatology Residency, 1997

University of Chicago Pritzker School of Medicine (Chicago, IL)
Internal Medicine Internship, 1994

University of Chicago Pritzker School of Medicine (Chicago, IL)
Medical Doctorate, 1993

Washington University (St. Louis, MO)
Bachelor of Arts in Philosophy, 1989

Professional Experience

Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN)
Investigator, 2004-Present

Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN)
Dermatologist, 1999-Present
Investigator, 2000-Present

Bellflower County Clinic (Indianapolis, IN)
Dermatologist (part-time), 1997-Present

Indiana University School of Medicine (Indianapolis, IN)
Volunteer Assistant Professor Clinical Dermatology, May 2011- Present

Indiana University School of Medicine (Indianapolis, IN)
Clinical Assistant Professor, 1997- May 2011

Dawes Dermatology Group (Indianapolis, IN)
Dermatologist, 1997-99

Honors and Awards

1996 Honorable Mention, Young Investigators Competition, Dermatol Surg
1992 Alpha Omega Alpha (AOA)
1989 Phi Beta Kappa
1989 Graduate with College Honors
1988 Genetics Society of America Summer Research Fellowship
1987-88 Scholarship and Leadership Award, Kappa Sigma National Fraternity

Scott Alfred Fretzin, MD

Clinical Study Experience (Other than Dawes Fretzin Clinical Research Group, LLC)

Genital Warts

Sponsor: 3M

Safety and efficacy trial evaluation 5% Imiquimod Cream application to external genital warts and an extended treatment area; *1999-02*

Diabetes

Sponsor: Takeda

Acting Agent: Quintiles, Inc.

An open-label, long-term extension study of voglibose (AO_128) in Type II Diabetes Mellitus patients; *March 1997 to June 1999*

Atopic Dermatitis

Sponsor: Connetics Therapeutics

An open-label, follow-on study of the safety and efficacy of Recombinant Interferon- γ 1b in subjects with moderate to severe atopic Dermatitis; *September 1996 to December 1998*

Atopic Dermatitis

Sponsor: Connetics Therapeutics

A Phase III study of the safety and efficacy of Recombinant Interferon- γ 1b in subjects with moderate to severe atopic Dermatitis; *September 1996 to April 1998*

Diabetes

Sponsor: Takeda

Acting Agent: Covance, Inc

A double-Blind, Placebo-Controlled, Randomized, Dose-Titration Study to Evaluate the Safety and Efficacy of Pioglitazone; *January 1997 to December 1998*

Scalp Psoriasis

Sponsor: Connetics Therapeutics

A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Betamethasone Valerate Foam in Treating Scalp Psoriasis; *April 1997 to December 1997*

Bronchitis

Sponsor: Bristol-Myers Squibb

A Double-blind Multicenter Comparative Study of Cefprozil (250mg bid) versus Cefuroxime Axetil (250mg bid) in the Treatment of Bronchitis; *December 1995 to April 1997*

Non-Insulin Dependent Diabetes Mellitus

Sponsor: Parke Davis

A 20-week, Double-Blind, Randomized Study of Troglitazone (CL-991) in patients with Non-Insulin Dependent Diabetes Mellitus; *June 1995 to May 1997*

Diabetes

Sponsor: Takeda

Acting Agent: Quintiles, Inc

A Randomized, Double-Blind, Placebo-Controlled, Six-Month, Safety and Efficacy Trial of 0.1, 0.5, 1, 2, 5 mg TID of Voglibose (AO-128) in Type II Diabetes Mellitus Patients; *October 1996 to December 1997*

Scott Alfred Fretzin, MD

Clinical Study Experience (Cont)

Osteoarthritis

Sponsor: Merck

A Double-Blind, Randomized, Multicenter Study to Compare the Safety of Dexibuprofen Lysine with Ibuprofen for Long-Term Treatment of Osteoarthritis; *September 1996 to June 1997*

Rheumatoid Arthritis

Sponsor: Boston Life Sciences, Inc

A Double-Blind, Randomized Study of Therafectin 6 grams/day compared to Placebo in Patients with Rheumatoid Arthritis Withdrawn from their Nonsteroidal Anti-Inflammatory Drug Therapy; *June 1996 to July 1997*

Psoriasis

Sponsor: Sergen, Inc

Phase II Randomized, Double-Blind, Placebo-Controlled Trial of DAB389IL-2 in Patients with Moderate to Severe Plaque-Type Psoriasis; *June 1995 to October 1996*

Xerostomia and Keratoconjunctivitis Sicca

Sponsor: Snowbrand Milk Products, Acting Agent: Pharmaco LSR

A pilot study of SNI-2011 in patients with Sjogren's Syndrome experiencing xerostomia and keratoconjunctivitis Sicca; *July 1995 to December 1996*

Intermittent Claudication

Sponsor: Marion Merrell Dow

Dose-Response Evaluation of Beraprost Sodium IR Tablets in Treatment of Intermittent Claudication; *October 1995 to December 1996*

Articles and Publications

Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, McColm J, Katcherian A, Cueto I, White T, Banerjee S, Hoffman RW. **"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis."** J Allergy Clin Immunol. 2012 Jul;130(1):145-154.e9. Epub 2012 Jun 5.

Gottlieb, A., Menter, A., Mendelsohn, A., Yaung-Kaung, S., Guzzo, C., Fretzin, S., Kunynetz, R., Kavanaugh, A. **"Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial."** Lancet, 2009 Feb 21; 373:633.

Papp, K., Bressinck, R., Fretzin, S., Goffe, B., Kempers, S., Gordon, K., Caro, I., Walicke, P., Wang, X., Mentor, A. **"Safety of efalizumab in adults with chronic Moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial."** International Journal of Dermatology, May 2006; Vol 45, Number 5: 605-614.

Crowley, J., Fretzin, S., Sobell, J. **"New Treatment Options for Psoriasis Involving the Hands and Feet."** Biologic Bulletin, March 2006.

Fretzin, S. **"Recent Advances in the Treatment of Psoriasis with Efalizumab Therapy."** US Dermatology Review, 2006 Issue II: 12-14.

Fretzin, S. **"Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis Involving the Hands and Feet with Raptiva®"** DermPA Today, Spring 2006; Vol 3, Number 1:4-5.

Fretzin, S. **"Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis Involving the Hands and Feet with Raptiva®"** DermNurse, Spring 2006; Vol 2, Number 1:3-4.

Scott Alfred Fretzin, MD

Articles and Publications (Cont)

- Fretzin, S. **“Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis Involving the Hands and Feet with Raptiva®”** Derm Resident, Spring 2006; Vol 5, Number 5:5-6.
- Fretzin S., Crowley, J., Jones, L., Young, M., Sobell, J. **“Successful Treatment of Hand And Foot Psoriasis with Efalizumab Therapy.”** Journal of Drugs in Dermatology. October 2006; Vol 5, Issue 9; 838-846.
- Fretzin S., Dawes K. *J Am Acad Dermatol* 2005; 52:P182. Abstract P2745.
- S. Fretzin. **“Answer All Your Patients’ Questions About STDs.”** Skin Aging 2000; 8 (8) :36-42.
- R. Huff, S. Fretzin, C. Lewis. **“Penile Eruption on a Diabetic Man.”** Arch Dermatol 1999; 135 :845.
- R Huff, S. Fretzin. **“Vesicular Eruption on the Chest and Back.”** Archives of Dermatology on the internet, 1998.
- S. Fretzin. **“Ringworm and Molluscum Contagiosum.”** Indiana Amateur Wrestling News-1997. pg 8.
- M. Fretzin, S. Fretzin, D. Fretzin. **“A Papulonecrotic Eruption in a Young Man.”** Arch Dermatol 1997; 133:1453-1458.
- T. Eads, S. Fretzin, C. Lewis. **“Pruritic, Painful Eruption.”** Arch Dermatol 1998; 134:231-236
- S. Fretzin. **“Introduction to the Terminology of Ethics.”** Ethics Workbook for Dermatology Residency Directors. 1998.
- S. Fretzin, W. Beeson, W. Hanke. **“Ignition Potential of the 585 nm Pulsed Dye Laser: Review of the Literature and Safety Recommendations.”** Dermatol Surg 1996; 22 699-702.
- G. Westhoven, S. Fretzin, C. Lewis. **“A Woman with Lung Cancer and Exfoliative Dermatitis.”** Arch Dermatol 1997; 133: 499-504.
- D. Fretzin, J. Sloan, K. Beer, S. Fretzin. **“Eccrine Syringofibroadenoma: A Clear Cell Variant.”** Am.J. of Dermatopathology 1995;17 (6): 591-593
- S. Fretzin, B. Allen, A. Vane Daal, S. Elgin. **“A Drosophila melanogaster H3.3 cDNA Encodes a Histone Variant Identical with the Vertebrate H3.3.”** Gene. 107 (1991) 341-342.
- F. Booyse, R. Bruce, M. Grover, S. Fretzin, J. Karkov, H. Modi, L. Casey. **“Rapid Release of Plasminogen Activators From Cultured Human Umbilical Vein Endothelial Cells.”** Blood. 66#5 (1985).

Presentations/Posters

World Congress of Dermatology. C. Leonardi, J. Sobell, S. Fretzin, H. Sofen, T. Hamilton, Y. Chen, C. Ivor, A. Menter. Phase IV Study to Evaluate the Safety and Efficacy of Efalizumab in the Treatment of Hand and Foot Plaque Psoriasis. October, 2007

68th SID Annual Meeting. A. Ehrlich, S. Fretzin, W. Werther, Y. Chen, I. Caro, D. Pariser. Prevalence of Cardiovascular Risk Factors by Psoriasis Severity in Biologic-Treated Patients: The RESPONSE Cohorts. May 9-12, 2007.

Australasian College of Dermatologists 39th Annual Scientific Meeting. S. Fretzin, K. Dawes, AC Rundle, I Caro. Safety of a topically applied novel small molecule inhibitor of the Hedgehog signaling pathway in subjects with basal cell carcinoma. May 14-17, 2006.

Scott Alfred Fretzin, MD

Presentations/Posters (Cont)

The American Academy of Dermatology Meeting (64th Annual). J. Sobell, S. Fretzin. Case studies of efalizumab in hand and foot psoriasis. March 3-7, 2006.

The American Academy of Dermatology Meeting. S. Fretzin, A. Menter, R. Langley, D. Cohen. Therapeutic Strategies and Treatments for Psoriasis (CME/CD-ROM). February, 2005.

The American Academy of Dermatology Meeting. S. Fretzin, K. Dawes. Efficacy and Safety of Efalizumab for Patients with Palmoplantar Pustulosis. February, 2005.

The American Academy of Dermatology Meeting. S. Fretzin, J. Cotton, A. Hood. Aleukemic Lymphoblastic Leukemia Cutis in a 14 month-old girl. San Francisco, California. 1997.

The American Society for Dermatopathology Meeting. J. Cotton, S. Fretzin, A. Hood. Cutaneous Lymphoblastic Lymphoma in children. Two case reports and review of the literature. San Francisco, California. March, 1997.

The United States and Canadian Academy of Pathology Meeting. J. Cotton, S. Fretzin, R. Neiman. Cutaneous Lymphoblastic Lymphoma in children. Two case reports and review of the literature. Orlando, Florida. March 1997.

St. Vincent's Hospital Dermatopathology Conference. S. Fretzin. Degos' Syndrome. January 1997.

St. Vincent's Hospital Dermatopathology Conference. S. Fretzin. Well's Syndrome. September 1996.

The American Academy of Dermatopathology Meeting, 1996. S. Fretzin, H. Faust. Atypical Cutaneous reaction to Benazepril with histologic features of Mycosis Fungoides.

The American Society for Cell Biology Regional Meeting. Poster Presentation. S. Elgin, A. Van daal, S. Fretzin, E. White, M. Gorovsky. "Histone Variants H2Avd and H3.3 of *Drosophila melanogaster*." March, 1990.

UCLA Symposium on Transcriptional Control of Cell Growth. A. Van daal, S. Fretzin, E. White, M. Gorovsky, S. Elgin. "Histone Variants H1Avd and H3.3. of *Drosophila melanogaster*." January, 1990.

Other Research Experience

- 1988-90 Washington University of St. Louis, Dept. of Biology, Sarah C. Elgin, Ph.D.; Characterization of *Drosophila melanogaster* Histone Variant Gene.
- 1986-88 Barnes Hospital, Dept. of Dermatology, Eugene Bauer, M.D.; Collagenase assays for research in Epidermolysis Bullosa.
- 1987 Michael Reese Hospital, Dept. of Immunology, Enrique Beckman M.D.; Gene Rearrangement of Lymphomas.
- 1985-86 Michael Reese Hospital, Dept. of Immunology, Françoise Booyse, Ph.D.; Release of Plasminogen activators from human endothelial cells.

Scott Alfred Fretzin, MD

License/Certifications

Board Certified in Dermatology, 1997
Indiana State License #01044060
ACLS Certified
CITI Certification, February 2012

Professional Societies

American Academy of Dermatology
Indiana Dermatologic Society
American Medical Association